Jazz Pharmaceuticals plc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.54%.
Did JAZZ Beat Earnings? Q2 2025 Results
Jazz Pharmaceuticals delivered a bruising second quarter, posting an adjusted loss of $8.25 per share that missed the $6.25 consensus estimate by 32.07%, while revenue of $1.05 billion edged fractionally below expectations despite growing 2.1% year over year. The quarter's defining event was a $905.36 million acquired in-process research and development charge tied to the Chimerix acquisition completed in April, which added dordaviprone to Jazz's oncology pipeline and drove the headline loss far beyond what analysts had modeled. Xywav remained the portfolio's clearest bright spot, generating $415.32 million in net product sales, up 13% year over year, while Epidiolex contributed $251.73 million; oncology softened to $274.15 million as Rylaze and Zepzelca each faced competitive headwinds. Looking ahead, Jazz narrowed its full-year revenue guidance to $4.15 billion to $4.30 billion while raising the floor of its non-GAAP adjusted EPS range, with near-term catalysts including a PDUFA date for dordaviprone on August 18 and Zepzelca's Priority Review decision due October 7.
- Xywav net product sales grew 13% YoY with approximately 625 net patient adds in Q2
- Total neuroscience revenue of $761.2 million, up 3% YoY
- Non-GAAP adjusted gross margin of 92.3%
- R&D expenses decreased YoY due to lower clinical study costs for zanidatamab and JZP385 discontinuation
“It has been a privilege to lead Jazz over my 22-year tenure. I am proud of what we have achieved on behalf of patients and confident that our new President and CEO, Renee Gala, will build on Jazz's momentum and serve as a catalyst in driving long-term growth.”
Jazz Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Jazz updated its full-year 2025 financial guidance: total revenue narrowed to $4.15–$4.30 billion (from $4.15–$4.40 billion), representing 4% growth at the midpoint. The lower end of GAAP net loss guidance was raised to $(565)–$(450) million or $(9.25)–$(7.50) per diluted share, driven by reductions in SG&A and R&D expenses and improvement in effective tax rate. Non-GAAP adjusted net income guidance is $300–$350 million or $4.80–$5.60 per diluted share (previously $250–$350 million or $4.00–$5.60). Key near-term catalysts include PDUFA dates for dordaviprone (August 18, 2025) and Zepzelca in 1L ES-SCLC (October 7, 2025), and top-line PFS data for zanidatamab in 1L GEA expected in 4Q25. Management remains confident Epidiolex/Epidyolex will achieve blockbuster status in 2025.
JAZZ YoY Financials
JAZZ Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.